Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
暂无分享,去创建一个
Dirk Hasenclever | Markus Loeffler | Christian Rübe | Norbert Schmitz | C. Rübe | N. Schmitz | M. Pfreundschuh | D. Hasenclever | M. Loeffler | A. Feller | L. Trümper | M. Reiser | H. Eimermacher | M. Kloess | Lorenz Trümper | Alfred C Feller | Michael Pfreundschuh | Marita Kloess | Rudolf Schmits | Christian Rudolph | Marcel Reiser | Dieter K Hossfeld | R. Schmits | Hartmut Eimermacher | D. Hossfeld | C. Rudolph
[1] References , 1971 .
[2] W. Hryniuk,et al. Dose intensity and lymphoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[5] C. Coltman,et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.
[6] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] K. Lennert,et al. CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study. , 1989, British Journal of Cancer.
[8] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[9] M. Pfreundschuh,et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[11] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[12] T. Miller,et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] V. Diehl,et al. Intensification of the CHOEP Regimen for High-Grade Non- Hodgkin’s Lymphoma by G-CSF: Feasibility of a 14-Day Regimen , 1994 .
[14] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.